Journal of Pediatric and Adolescent Gynecology
Volume 22, Issue 3 , Pages 143-149 , June 2009

Menstrual Suppression for Adolescents with Developmental Disabilities

Reference 

  1. Dizon CD, Allen LM, Ornstein MP. Menstrual and contraceptive issues among young women with developmental delay: a retrospective review of cases at the Hospital for Sick Children, Toronto. J Pediatr Adolesc Gynecol. 2005;18:157
  2. Kaunitz AM. Long-acting injectable contraception with depot medroxyprogesterone acetate. Am J Obstet Gynecol. 1994;170:1543
  3. Isart F, Weber FT, Merrick CL, et al. Use of injectable progestin (medroxyprogesterone acetate) in adolescent health care. Contraception. 1992;46:41
  4. Chamberlain A, Rauh J, Passer A, et al. Issues in fertility control for mentally retarded female adolescents: I. Sexual activity, sexual abuse, and contraception. Pediatrics. 1984;73:445
  5. Quint EH. The conservative management of abnormal bleeding in teenagers with developmental disabilities. J Pediatr Adolesc Gynecol. 2003;16:54
  6. Jones KP, Wild RA. Contraception for patients with psychiatric or medical disorders. Am J Obstet Gynecol. 1994;170:1575
  7. Mattson RH, Cramer JA, Caldwell BV, et al. Treatment of seizures with medroxyprogesterone acetate: preliminary report. Neurology. 1984;34:1255
  8. Frederiksen MC. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med. 1996;41:414
  9. Quint EH, Elkins TE, Sorg CA, et al. The treatment of cyclical behavioral changes in women with mental disabilities. J Pediatr Adolesc Gynecol. 1999;12:139
  10. Moore LL, Valuck R, McDougall C, et al. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception. 1995;52:215
  11. Mainwaring R, Hales HA, Stevenson K, et al. Metabolic parameter, bleeding, and weight changes in U.S. women using progestin only contraceptives. Contraception. 1995;51:149
  12. Tuchman LK, Huppert JS, Huang B, et al. Adolescent use of the monthly contraceptive injection. J Pediatr Adolesc Gynecol. 2005;18:255
  13. Bahamondes L, Del CS, Tabares G, et al. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception. 2001;64:223
  14. Espey E, Steinhart J, Ogburn T, et al. Depo-provera associated with weight gain in Navajo women. Contraception. 2000;62:55
  15. Mia AR, Siddiqui NI, Khan MR, et al. Effect of prolonged use of injectable hormonal contraceptives on blood pressure and body weight. Mymensingh Med J. 2004;13:30
  16. Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2002;15:79
  17. Bonny AE, Britto MT, Huang B, et al. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol. 2004;17:109
  18. Black A, Francoeur D, Rowe T. SOGC Clinical Practice Guidelines No. 143-Part 2 of 3. Canadian Contraception Consensus. J Obstet Gynaecol Can. 2004;26:219
  19. Boroditsky R, Guilbert E. SOGC Committee Opinion No. 94. Injectable Medroxyprogesterone Acetate for Contraception. J Soc Obstet Gynaecol Can. 2000;22:616
  20. Rees HD, Bonsall RW, Michael RP. Pre-optic and hypothalamic neurons accumulate [3H]medroxyprogesterone acetate in male cynomolgus monkeys. Life Sci. 1986;39:1353
  21. Cromer BA, Scholes D, Berenson A, et al. Depot medroxyprogesterone acetate and bone mineral density in adolescents–the Black Box Warning: a Position Paper of the Society for Adolescent Medicine. J Adolesc Health. 2006;39:296
  22. Cromer BA, Blair JM, Mahan JD, et al. A prospective comparison of bone density in adolescent girls receiving depot medroxyprogesterone acetate (Depo-Provera), levonorgestrel (Norplant), or oral contraceptives. J Pediatr. 1996;129:671
  23. Cromer BA, Stager M, Bonny A, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434
  24. Busen NH, Britt RB, Rianon N. Bone mineral density in a cohort of adolescent women using depot medroxyprogesterone acetate for one to two years. J Adolesc Health. 2003;32:257
  25. Lara-Torre E, Edwards CP, Perlman , et al. Bone mineral density in adolescent females using depot medroxyprogesterone acetate. J Pediatr Adolesc Gynecol. 2004;17:17
  26. Scholes D, LaCroix AZ, Ichikawa LE, et al. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139
  27. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol. 1997;89:179
  28. Kwiecien M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial. Contraception. 2003;67:9
  29. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial. Obstet Gynecol. 2001;98:771
  30. Cachrimanidou AC, Hellberg D, Nilsson S, et al. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception. 1993;48:205
  31. Anderson FD, Hait H. A multicenter, randomized study of an extended cycle oral contraceptive. Contraception. 2003;68:89
  32. Machado RB, Fabrini P, Cruz AM, et al. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 microg) and gestodene (75 microg). Contraception. 2004;70:365
  33. Miller L, Hughes JP. Continuous combination oral contraceptive pills to eliminate withdrawal bleeding: a randomized trial. Obstet Gynecol. 2003;101:653
  34. Rosenberg MJ, Waugh MS, Meehan TE. Use and misuse of oral contraceptives: risk indicators for poor pill taking and discontinuation. Contraception. 1995;51:283
  35. Wang E, Shi S, Cekan SZ, et al. Hormonal consequences of “missing the pill”. Contraception. 1982;26:545
  36. Fraser IS, Jansen RP. Why do inadvertent pregnancies occur in oral contraceptive users? Effectiveness of oral contraceptive regimens and interfering factors. Contraception. 1983;27:531
  37. Anderson FD, Hait H, Hsiu J, et al. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen. Contraception. 2005;71:55
  38. Janssen-Ortho Inc. Evra Product Monograph. 2006.
  39. Weisberg F, Bouchard C, Moreau M, et al. Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. J Obstet Gynaecol Can. 2005;27:350
  40. Rubinstein ML, Halpern-Felsher BL, Irwin CE. An evaluation of the use of the transdermal contraceptive patch in adolescents. J Adolesc Health. 2004;34:395
  41. Harel Z, Riggs S, Vaz R, et al. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol. 2005;18:85
  42. Audet MC, Moreau M, Koltun WD, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001;285:2347
  43. Stewart FH, Kaunitz AM, Laguardia KD, et al. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol. 2005;105:1389
  44. Zieman M, Guillebaud J, Weisberg E, et al. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77:S13
  45. Burkman RT. The transdermal contraceptive system. Am J Obstet Gynecol. 2004;190:S49
  46. Ortho: ORTHO EVRA Product Monograph, 2007
  47. Jick SS, Kaye JA, Russmann S, et al. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2006;73:223
  48. Jick S, Kaye JA, Li L, et al. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007;76:4
  49. Cole JA, Norman H, Doherty M, et al. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109:339
  50. Jensen JT. Contraceptive and therapeutic effects of the levonorgestrel intrauterine system: an overview. Obstet Gynecol Surv. 2005;60:604
  51. Barbosa I, Bakos O, Olsson SE, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception. 1990;42:51
  52. Silverberg SG, Haukkamaa M, Arko H, et al. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol. 1986;5:235
  53. Suvisaari J, Lahteenmaki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception. 1996;54:201
  54. Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception. 2002;65:129
  55. Radesic B, Sharma A. Levonorgestrel-releasing intrauterine system for treating menstrual disorders: a patient satisfaction questionnaire. Aust N Z J Obstet Gynaecol. 2004;44:247
  56. Haefner HK, Elkins TE. Contraceptive management for female adolescents with mental retardation and handicapping disabilities. Curr Opin Obstet Gynecol. 1991;3:820
  57. Van HK, van Kaam KJ, van Grootheest AC, et al. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception. 2006;73:257
  58. Suhonen S, Haukkamaa M, Jakobsson T, et al. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. Contraception. 2004;69:407
  59. Farley TM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet. 1992;339:785
  60. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)—a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol. 2006;125:9

PII: S1083-3188(07)00309-9

doi: 10.1016/j.jpag.2007.10.008

Journal of Pediatric and Adolescent Gynecology
Volume 22, Issue 3 , Pages 143-149 , June 2009

Article Tools